Navigation Links
Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting

REDWOOD CITY, Calif., May 02, 2007 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. announced today that a presentation was made today at the 20th International Conference on Antiviral Research being held in Palm Springs, California, on a non-nucleoside hepatitis C virus (HCV) polymerase inhibitor discovered by Genelabs.

The oral presentation was given by Christopher D. Roberts, Ph.D., Director of Medicinal Chemistry at Genelabs, entitled "GL59728: A Potent Allosteric Inhibitor of the HCV NS5b RNA Dependent RNA Polymerase with Excellent Pharmacokinetic Properties."

GL59728 is one of a number of non-nucleoside HCV polymerase inhibitors discovered by Genelabs. In the presentation, Dr. Roberts outlined the lead optimization of certain non-nucleoside HCV polymerase inhibitors through an iterative process involving testing for potency in directly inhibiting HCV NS5b polymerase, inhibiting the replication of an HCV sub-genomic replicon, and pharmacokinetic properties.

The optimized lead that emerged from this chemistry approach, one of several taken by Genelabs, is known as GL59728. The IC50 of GL59728 for inhibition of the HCV NS5b polymerase is 16 nanomolar and the EC50 for inhibition of HCV replicon is 170 nanomolar. Further, GL59728 shows excellent oral bioavailability, exceeding 50% in all four species tested, including higher-order species, low clearance and a half-life consistent with once- or twice-daily dosing. The tissue distribution of GL59728 also appears favorable; since its concentration is enhanced several fold in liver, the site of HCV infection, relative to that obtained in plasma. Importantly, GL59728 was also tested in combination with other classes of HCV antiviral compounds, including a nucleoside chain terminator, a protease inhibitor and interferon alpha, and shown to be additive in activity with each.

In June 2006 Genelabs entered into a license and research co
'"/>




Page: 1 2 3

Related medicine technology :

1. Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
3. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
4. Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction
5. Micell Technologies Presents Data on Novel Drug-Eluting Stents
6. OncoGenex Technologies Announces Phase II Data of OGX-011 in Metastatic Breast Cancer at American Association for Cancer Research 2007 Annual Meeting
7. AVAX Technologies Presents Results of Phase I-II M-Vax Trial at Annual Meeting of American Association for Cancer Research
8. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
(Date:8/29/2014)... 2014 According to a ... Extraction type (SFE, Cold Pressed, Organic Solvent, & Others), ... Food Supplements, Fragrance, & Others) - Global Trends & ... segments the Amaranth Seed Oil Market with an ... terms of value. The Amaranth Seed Oil Market ...
(Date:8/29/2014)... SPRING, Md. , Aug. 29, 2014  United ... that the U.S. District Court for the District of ... its favor in the company,s case against Sandoz, Inc. ... Judge Peter Sheridan ruled that U.S. Patent ... Inc., and enjoined Sandoz from marketing its generic product ...
(Date:8/29/2014)... Aug. 29, 2014 Diseases largely eradicated in ... ago are returning. Measles was declared eliminated in 2000, ... as of August 15—the highest incidence in 20 years. ... department declared whooping cough a problem of "epidemic ... sick and dying from these preventable diseases—in part because ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4District Court Decision Received In Remodulin Patent Case 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3
... Oct. 10, 2011 IRIDEX Corporation (Nasdaq: IRIX ... named President and Chief Executive Officer effective today. Dr. Beck ... become Chief Technology Officer, and will also replace Mr. Boutacoff ... 47, has spent the majority of his career in leadership ...
... Cantel Medical Corp. (NYSE: CMN ) will ... ended July 31, 2011 on Thursday, October 13 before the ... results at 11:00 AM ET.  Participating in the call will ... CEO; Seth R. Segel, Executive Vice President; and Craig A. ...
Cached Medicine Technology:IRIDEX Names Veteran Healthcare Executive Dominik Beck President, CEO 2IRIDEX Names Veteran Healthcare Executive Dominik Beck President, CEO 3IRIDEX Names Veteran Healthcare Executive Dominik Beck President, CEO 4Cantel Medical Corp. to Hold Conference Call to Discuss Fourth Quarter and Fiscal 2011 Results 2
(Date:8/30/2014)... (PRWEB) August 30, 2014 Serving contented ... in India, Profit By Outsourcing is now offering ... services. The company gives emphasize on putting forward the ... product to clients. Their dedicated team of professionals and ... results. They can handle even the critical issues of ...
(Date:8/30/2014)... 30, 2014 "I had a handicapped friend ... crutches," said an inventor from Wetumpka, Ala. "In order to ... of the shore, I came up with a way for ... created a prototype for the patent-pending Deezers to allow crutches ... individual to use crutches, walkers, or canes at the beach. ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 In today’s ... and increasingly difficult to get. Snoring and sleep apnea ... and breathing stops) robs people and their bed partners ... challenges. Up to 45% of the population snores and ... sleep apnea. Of these, only 10% have been diagnosed ...
(Date:8/30/2014)... The new review published by Daily Gossip ... Karen Brimeyer, who wanted to make her guide accessible to ... is now easy to find in the form of an ... the author of the new method shares all her tips ... writes in its review that the leaky gut syndrome can ...
(Date:8/30/2014)... 2014 LiveStreamingFitness.com, a company dedicated to providing ... lifestyle resources, is proud to announce it has been recognized ... home fitness solutions by ABC’s Good Morning America. ... ABC’s Good Morning America, “Live Streaming Fitness is the hottest ... day by streamlining your workout…to boot camp at Life Streaming ...
Breaking Medicine News(10 mins):Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Leaky Gut Cure Review Reveals Unique Method to Stop Chronic Symptoms 2Health News:LiveStreamingFitness.com is New Trend In Fitness 2
... System for Rapid Testing for Infectious Diseases Incorporates the ... ARBOR, Mich., May 18 BD Diagnostics, a segment ... BDX ), and HandyLab, Inc. announced today that they ... commercialize its molecular assays on a new BD MAX(TM) ...
... Payment Support Insurance Industry Corporate GreeningSAN DIEGO and ... a leading provider of medical cost containment, provider ... over 70% of U.S. automotive insurance payers, and ... and Gateway Services to Workers, Compensation, Auto Medical ...
... be presented on Abbott,s market-leading XIENCE V(R) stent- Educational ... stent in developmentBARCELONA, Spain, May 18 Abbott (NYSE: ... of major events and news announcements during EuroPCR 2009 ... presentation of new data from the SPIRIT V post-approval, ...
... and PrEP Research and Calls for Urgent Coordination and Leadership ... "It,s an exciting time in HIV prevention research. We will ... research trials this year, as well as see the start ... answers in the years to come," said Mitchell Warren, AVAC ...
... SAN DIEGOCystic fibrosis patients may benefit from a new ... mucous, which is a key factor in the disease, ... The research will be presented on Sunday, May 17, ... San Diego., "Our results suggest that we have identified ...
... help physicians solve a perennial problem: patients who don,t ... the Kaiser Permanente Center for Health Research, in Portland, ... patients with asthma to fill or refill their prescriptions ... be presented on May 17 at the 105th International ...
Cached Medicine News:Health News:BD and HandyLab Announce Exclusive Collaboration to Commercialize Molecular Assays 2Health News:BD and HandyLab Announce Exclusive Collaboration to Commercialize Molecular Assays 3Health News:BD and HandyLab Announce Exclusive Collaboration to Commercialize Molecular Assays 4Health News:Mitchell and Jopari Say 'Green Transaction Initiatives' Play Key Role in P&C and Group Health Industry Environmental Best Practices 2Health News:Mitchell and Jopari Say 'Green Transaction Initiatives' Play Key Role in P&C and Group Health Industry Environmental Best Practices 3Health News:Mitchell and Jopari Say 'Green Transaction Initiatives' Play Key Role in P&C and Group Health Industry Environmental Best Practices 4Health News:Abbott Announces EuroPCR 2009 Activities 2Health News:Abbott Announces EuroPCR 2009 Activities 3Health News:Abbott Announces EuroPCR 2009 Activities 4Health News:Piecing Together the HIV Prevention Puzzle 2Health News:Piecing Together the HIV Prevention Puzzle 3Health News:Piecing Together the HIV Prevention Puzzle 4Health News:Sodium channel blocker shows promise as a potential treatment for cystic fibrosis 2Health News:Increasing ICS compliance: The voice may be recorded, but the results are real 2Health News:Increasing ICS compliance: The voice may be recorded, but the results are real 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: